Compare GSK plc (GSK) vs TotalEnergies SE (TTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs TotalEnergies SE — how do they compare? GSK plc trades at $50.42 (market cap $102.60B), while TotalEnergies SE trades at $87.48 (market cap $196.06B). The key difference: TotalEnergies SE is the larger of the two by market cap, and TotalEnergies SE pays the higher dividend (4.82%). Which is the better fit depends on your goals.
| GSK | TTE | |
|---|---|---|
Market Cap | $102.60B | $196.06B |
Sector | Health | Energy |
52-Week High | $61.18 | $93.60 |
52-Week Low | $38.22 | $57.39 |
Enterprise Value | $123.04B | $227.06B |
Dividend Yield | 3.57% | 4.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.30, down 3.57% today, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates of $1.27, and announced a $2.52 billion cost-saving plan through 2029. Revenue growth remains steady at 5% constant currency, supported by vaccines and specialty medicines. Analyst consensus shows 31% buy ratings with 55% hold, indicating cautious optimism.
GSK's solid profitability and strategic cost initiatives support long-term growth, but near-term stock performance faces headwinds from bearish technicals and mixed analyst sentiment. Key risks include pipeline execution and regulatory challenges, while institutional ownership trends and recent FDA approvals provide stability. The current valuation at 16.02 P/E offers reasonable entry for patient investors.
TotalEnergies (TTE) trades at $87.49, down 0.53% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $94.00. The company reported mixed recent earnings, missing in Q4 2025 but beating in Q1 and Q2 2026, while revenue has declined from $263.3B in 2022 to $182.3B in 2025. Recent strategic moves include acquiring Shell's European onshore renewables business and developing the Cronos gas field in Cyprus, signaling a shift toward integrated energy.
TTE presents a value opportunity with a low P/E of 11.01 and strong cash flow, but faces headwinds from declining revenue and regulatory climate litigation. The stock's upside is supported by analyst bullishness and dividend payments, yet investors must weigh energy transition execution risks against its current attractive valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →
